cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29467475
title: Evaluating muscle characteristics and fall events: insights from real-world longitudinal data

description: To compare the relationship between the delta values of muscle quantity (thickness) and muscle quality (grayscale) in the paretic and nonparetic lower extremities and the incidence of falls within 3 months. Muscle quality and quantity can significantly influence lower limb muscle strength in patients, potentially contributing to fall-related incidents. Rehabilitation department of the largest rehabilitation center in Southwest China’s Yunnan Province. Patients with hemiplegic stroke or traumatic brain injury within the preceding 3 months. Exclusion criteria included the presence of other primary diseases that could contribute to muscle loss. Baseline characteristics, muscle thickness and grayscale measurements, inflammatory biomarkers, and total cholesterol levels were collected to evaluate patient-specific factors associated with subsequent falls after a 3-month period. Compared with patients with a manual muscle testing (MMT) score ≥3, those with an MMT score &lt;3 exhibited significant differences in the rectus femoris (RF) (<i>p</i> = 0.002) and long head of biceps thickness of the affected limb (<i>p</i> = 0.033). The vastus intermedius, gastrocnemius (GM), and vastus medialis were more prominent in patients with an MMT score ≥3 (<i>p</i> = 0.045, 0.005, and 0.032, respectively). The primary distinction between the affected and unaffected limbs in both MMT groups was observed in the delta values of grayscale rather than in muscle thickness. Notably, 38.8% of patients with an MMT score &lt;3 experienced at least one fall over 3 months, compared with an 8.69% fall rate among those with an MMT score ≥3 (<i>p</i> = 0.028). Initial changes in procalcitonin and cholesterol levels exhibited a stronger correlation with gait function than baseline measurements of muscle thickness or grayscale. The delta values in RF muscle thickness and delta value of GM grayscale were significantly associated with the incidence of subsequent falls after 3 months period. Real-world, longitudinal data suggest that muscle grayscale, rather than muscle thickness, may offer superior prognostic insights. The likelihood of a falling event was elevated in patients with an MMT score &lt;3, particularly among those with significant disparities in GM grayscale values between affected and unaffected limbs.
DOI: 10.6084/m9.figshare.29467475.v1
title: Evaluating muscle characteristics and fall events: insights from real-world longitudinal data

description: To compare the relationship between the delta values of muscle quantity (thickness) and muscle quality (grayscale) in the paretic and nonparetic lower extremities and the incidence of falls within 3 months. Muscle quality and quantity can significantly influence lower limb muscle strength in patients, potentially contributing to fall-related incidents. Rehabilitation department of the largest rehabilitation center in Southwest China’s Yunnan Province. Patients with hemiplegic stroke or traumatic brain injury within the preceding 3 months. Exclusion criteria included the presence of other primary diseases that could contribute to muscle loss. Baseline characteristics, muscle thickness and grayscale measurements, inflammatory biomarkers, and total cholesterol levels were collected to evaluate patient-specific factors associated with subsequent falls after a 3-month period. Compared with patients with a manual muscle testing (MMT) score ≥3, those with an MMT score &lt;3 exhibited significant differences in the rectus femoris (RF) (<i>p</i> = 0.002) and long head of biceps thickness of the affected limb (<i>p</i> = 0.033). The vastus intermedius, gastrocnemius (GM), and vastus medialis were more prominent in patients with an MMT score ≥3 (<i>p</i> = 0.045, 0.005, and 0.032, respectively). The primary distinction between the affected and unaffected limbs in both MMT groups was observed in the delta values of grayscale rather than in muscle thickness. Notably, 38.8% of patients with an MMT score &lt;3 experienced at least one fall over 3 months, compared with an 8.69% fall rate among those with an MMT score ≥3 (<i>p</i> = 0.028). Initial changes in procalcitonin and cholesterol levels exhibited a stronger correlation with gait function than baseline measurements of muscle thickness or grayscale. The delta values in RF muscle thickness and delta value of GM grayscale were significantly associated with the incidence of subsequent falls after 3 months period. Real-world, longitudinal data suggest that muscle grayscale, rather than muscle thickness, may offer superior prognostic insights. The likelihood of a falling event was elevated in patients with an MMT score &lt;3, particularly among those with significant disparities in GM grayscale values between affected and unaffected limbs.
DOI: 10.6084/m9.figshare.29467689
title: Efficacy and safety of remimazolam combined with remifentanil for sedation during awake fiberoptic intubation: a randomized controlled trial

description: There has been not study determining if remimazolam combined with remifentanil is the reasonable dosing regimen for sedation during awake fiberoptic intubation (AFOI). This prospective double-blind randomized controlled trial compare efficacy and safety of sedation using different-dose remimazolam combined with remifentanil for AFOI procedure. One hundred and fifty patients were randomly assigned to five groups receiving different interventions. The Rf group received only remifentanil infusion of 0.05 mcg/kg/min, the Rm group received only remimazolam 0.6 mg/kg/h, and the RR0.2, RR0.4 and RR0.6 groups received remifentanil 0.05 mcg/kg/min combined with remimazolam of 0.2, 0.4 and 0.6 mg/kg/h, respectively. After intravenous infusion of studied drugs for 3 min, AFOI was carried out under airway topical anesthesia. The primary outcome was the incidence of deep sedation during AFOI procedure. Deep sedation occurred only in the Rm, RR0.4 and RR0.6 groups, with incidences of 3.3%, 17.2%, and 50.0%, respectively (<i>p &lt;</i> 0.001). The incidence of deep sedation in the RR0.6 group was not statistically different from that in the RR0.4 group (<i>p &gt;</i> 0.05), but was higher than these in the Rf, Rm and RR0.2 groups (<i>p &lt;</i> 0.05<i>).</i> Hypoxemia was observed only in RR0.2, RR0.4 and RR0.6 groups, with incidences of 13.3%, 44.8%, and 44.8%, respectively (<i>p &lt;</i> 0.001). The recall score for AFOI procedure was significantly lower in the four remimazolam groups than in the Rf group (<i>p &lt;</i> 0.005). The patients’ reaction score to AFOI procedure, cough severity, incidence of tachycardia, and willingness to repeat the procedure were lower in the RR0.6 group than in the Rf and Rm groups (<i>p &lt;</i> 0.005). Remimazolam 0.2–0.6 mg/kg/h combined with remifentanil 0.05 mcg/kg/min are effective and feasible dosing regimens of sedation for AFOI procedure in patients with normal airway, but the regimen including remimazolam 0.2 mg/kg/h should be the better choice for balancing efficacy and safety. Chinese Clinical Trial Registry, ChiCTR2100042917. Retrieved from http://www.chictr.org.cn/showproj.html?proj=65332 on January 31, 2021.
DOI: 10.6084/m9.figshare.29467689.v1
title: Efficacy and safety of remimazolam combined with remifentanil for sedation during awake fiberoptic intubation: a randomized controlled trial

description: There has been not study determining if remimazolam combined with remifentanil is the reasonable dosing regimen for sedation during awake fiberoptic intubation (AFOI). This prospective double-blind randomized controlled trial compare efficacy and safety of sedation using different-dose remimazolam combined with remifentanil for AFOI procedure. One hundred and fifty patients were randomly assigned to five groups receiving different interventions. The Rf group received only remifentanil infusion of 0.05 mcg/kg/min, the Rm group received only remimazolam 0.6 mg/kg/h, and the RR0.2, RR0.4 and RR0.6 groups received remifentanil 0.05 mcg/kg/min combined with remimazolam of 0.2, 0.4 and 0.6 mg/kg/h, respectively. After intravenous infusion of studied drugs for 3 min, AFOI was carried out under airway topical anesthesia. The primary outcome was the incidence of deep sedation during AFOI procedure. Deep sedation occurred only in the Rm, RR0.4 and RR0.6 groups, with incidences of 3.3%, 17.2%, and 50.0%, respectively (<i>p &lt;</i> 0.001). The incidence of deep sedation in the RR0.6 group was not statistically different from that in the RR0.4 group (<i>p &gt;</i> 0.05), but was higher than these in the Rf, Rm and RR0.2 groups (<i>p &lt;</i> 0.05<i>).</i> Hypoxemia was observed only in RR0.2, RR0.4 and RR0.6 groups, with incidences of 13.3%, 44.8%, and 44.8%, respectively (<i>p &lt;</i> 0.001). The recall score for AFOI procedure was significantly lower in the four remimazolam groups than in the Rf group (<i>p &lt;</i> 0.005). The patients’ reaction score to AFOI procedure, cough severity, incidence of tachycardia, and willingness to repeat the procedure were lower in the RR0.6 group than in the Rf and Rm groups (<i>p &lt;</i> 0.005). Remimazolam 0.2–0.6 mg/kg/h combined with remifentanil 0.05 mcg/kg/min are effective and feasible dosing regimens of sedation for AFOI procedure in patients with normal airway, but the regimen including remimazolam 0.2 mg/kg/h should be the better choice for balancing efficacy and safety. Chinese Clinical Trial Registry, ChiCTR2100042917. Retrieved from http://www.chictr.org.cn/showproj.html?proj=65332 on January 31, 2021.
DOI: 10.6084/m9.figshare.29663059
title: Protocol for the HALDI study—conceptual framework for investigating health and living conditions in an arctic area of Sweden with a multiethnic population

description: Despite increasing research interest in the health and well-being of the Indigenous Sámi people, knowledge remains fragmented and insufficient. The HALDI study aims to examine health status, well-being, and associated determinants within a multi-ethnic context, focusing on the Sámi people in Sweden. This protocol outlines the study’s objectives, design, and methodology, with the goal of generating representative data to inform future research, policy, and interventions targeting Sámi health. To ensure relevance, initial focus groups discussions identified key health issues for the Sámi people in Swedish Sápmi. Based on these findings, a comprehensive questionnaire was developed, encompassing socioeconomic status, ethnicity, psychiatric and somatic disorders, and self-perceived health. All adults in Jokkmokk municipality (<i>n</i> = 4077) were invited to participate. The following year, a clinical examination was conducted, including measures such as blood pressure, pulse, height, weight, blood sampling, and an updatet questionnaire on health status, dietary habits, and, for those aged 65 years and above, assessments of frailty and cognition. A total of 1682 individuals (41%) responded to the first questionnaire; 68% identified as Swedish, 22% as Sámi, and 7% with other ethnic identities. In the clinical study, 706 participated with similar ethnic proportions. This is the first study in Sweden to incorporate ethnic self-identification in a multi-ethnic population. By presenting the study protocol and sample characteristics, we highlight the potential for future analyses to inform evidence-based health interventions and policy to improve outcomes for the multi-ethnic Arctic population.
DOI: 10.6084/m9.figshare.29663059.v1
title: Protocol for the HALDI study—conceptual framework for investigating health and living conditions in an arctic area of Sweden with a multiethnic population

description: Despite increasing research interest in the health and well-being of the Indigenous Sámi people, knowledge remains fragmented and insufficient. The HALDI study aims to examine health status, well-being, and associated determinants within a multi-ethnic context, focusing on the Sámi people in Sweden. This protocol outlines the study’s objectives, design, and methodology, with the goal of generating representative data to inform future research, policy, and interventions targeting Sámi health. To ensure relevance, initial focus groups discussions identified key health issues for the Sámi people in Swedish Sápmi. Based on these findings, a comprehensive questionnaire was developed, encompassing socioeconomic status, ethnicity, psychiatric and somatic disorders, and self-perceived health. All adults in Jokkmokk municipality (<i>n</i> = 4077) were invited to participate. The following year, a clinical examination was conducted, including measures such as blood pressure, pulse, height, weight, blood sampling, and an updatet questionnaire on health status, dietary habits, and, for those aged 65 years and above, assessments of frailty and cognition. A total of 1682 individuals (41%) responded to the first questionnaire; 68% identified as Swedish, 22% as Sámi, and 7% with other ethnic identities. In the clinical study, 706 participated with similar ethnic proportions. This is the first study in Sweden to incorporate ethnic self-identification in a multi-ethnic population. By presenting the study protocol and sample characteristics, we highlight the potential for future analyses to inform evidence-based health interventions and policy to improve outcomes for the multi-ethnic Arctic population.
DOI: 10.6084/m9.figshare.29889142
title: Therapeutic effects of topical Mycophenolate mofetil on hydroquinone-induced depigmentation in Guinea pigs and mice

description: Vitiligo is a depigmentation disorder with an undefined specific pathogenesis, with the autoimmune theory being a prominent etiology. Mycophenolate mofetil (MMF), a novel immunosuppressant, selectively inhibits inosine 5-monophosphate dehydrogenase (IMPDH), crucial for lymphocyte DNA synthesis. Recent research has highlighted MMF’s efficacy in vitiligo treatment; however, the precise mechanism remains unclear. This study aimed to explore the therapeutic impact and mechanism of vitiligo. We enrolled guinea pigs and C57/BL6 mice which were randomly divided into the hydroquinone group, the MMF & hydroquinone group, and the control group. Skin biopsy specimens were collected from designated areas which were stained using hematoxylin and eosin (H&E), Masson-Fontana (M-F), and immunofluorescence techniques. To elucidate the pharmacological mechanisms underlying the effects of MMF, real-time polymerase chain reaction (PCR) and western blotting analyses were performed. A comparative analysis revealed a notable enhanced pigmentation in the MMF-conjunction group. Subsequent to MMF application, there was a significant augmentation in both the number of melanocytes within the basal layer and melanin-containing hair follicles. MMF activated tyrosinase (TYR), which had been suppressed by hydroquinone, and led to an upregulation of melanin-associated genes such as TYR, TYRP-1, MITF, and SILV. Additionally, there was an increase in WNT pathway-related proteins, including β-catenin, GSK3β, Axin2, Dkk, and Dact2. MMF effectively mitigated the vitiligo-like increase in IFN-γ induced by hydroquinone safely. MMF exhibits a notable capacity to ameliorate the pigment-loss effect associated with hydroquinone through the activation of the WNT signaling pathway. Consequently, MMF emerges as a promising therapeutic agent for mitigating skin pigmentation.
DOI: 10.6084/m9.figshare.29889142.v1
title: Therapeutic effects of topical Mycophenolate mofetil on hydroquinone-induced depigmentation in Guinea pigs and mice

description: Vitiligo is a depigmentation disorder with an undefined specific pathogenesis, with the autoimmune theory being a prominent etiology. Mycophenolate mofetil (MMF), a novel immunosuppressant, selectively inhibits inosine 5-monophosphate dehydrogenase (IMPDH), crucial for lymphocyte DNA synthesis. Recent research has highlighted MMF’s efficacy in vitiligo treatment; however, the precise mechanism remains unclear. This study aimed to explore the therapeutic impact and mechanism of vitiligo. We enrolled guinea pigs and C57/BL6 mice which were randomly divided into the hydroquinone group, the MMF & hydroquinone group, and the control group. Skin biopsy specimens were collected from designated areas which were stained using hematoxylin and eosin (H&E), Masson-Fontana (M-F), and immunofluorescence techniques. To elucidate the pharmacological mechanisms underlying the effects of MMF, real-time polymerase chain reaction (PCR) and western blotting analyses were performed. A comparative analysis revealed a notable enhanced pigmentation in the MMF-conjunction group. Subsequent to MMF application, there was a significant augmentation in both the number of melanocytes within the basal layer and melanin-containing hair follicles. MMF activated tyrosinase (TYR), which had been suppressed by hydroquinone, and led to an upregulation of melanin-associated genes such as TYR, TYRP-1, MITF, and SILV. Additionally, there was an increase in WNT pathway-related proteins, including β-catenin, GSK3β, Axin2, Dkk, and Dact2. MMF effectively mitigated the vitiligo-like increase in IFN-γ induced by hydroquinone safely. MMF exhibits a notable capacity to ameliorate the pigment-loss effect associated with hydroquinone through the activation of the WNT signaling pathway. Consequently, MMF emerges as a promising therapeutic agent for mitigating skin pigmentation.
DOI: 10.6084/m9.figshare.30132047
title: Effect of press needle stimulation on postoperative pulmonary complications in video-assisted thoracoscopic surgery patients: a randomized controlled trial

description: Patients undergoing high-risk surgical procedures frequently experience postoperative pulmonary complications (PPCs) that impact outcomes. Acupuncture has demonstrated potential benefits during surgery. Press needle stimulation is increasingly recognized as an alternative to conventional techniques. We aimed to evaluate the effect of press needle stimulation on PPCs in patients with lung cancer undergoing video-assisted thoracoscopic surgery. Eighty-seven patients undergoing video-assisted thoracoscopic surgery were randomized into press needle (<i>n</i> = 48) or sham needle (<i>n</i> = 39) groups. The press needle group underwent bilateral stimulation of acupoints LU9 (Taiyuan), RN17 (Danzhong), LU6 (Kongzui), and BL13 (Feishu) before anesthesia and during surgery. The sham group received a placebo stimulation. The primary endpoint was the incidence of PPCs within seven days post-surgery. The secondary endpoints included cytokine levels, intraoperative respiratory mechanics, postoperative pain score, analgesic consumption, and related complications. Press needle acupoint stimulation was associated with a significantly lower incidence of PPCs than the sham needle group. Perioperative data, tachycardia, cough, postoperative nausea, vomiting, and most inflammatory markers exhibited no significant differences, except for lower hypoxia-inducible factor-1<i>α</i> levels in the press needle group. Hemodynamic and blood gas analyses indicated no significant cardiovascular or respiratory differences between groups. The press needle group exhibited reduced patient-controlled analgesia (PCA) pump utilization and lower total PCA usage, indicating improved pain management. This study indicates that press needle stimulation lowers PPC incidence and improves postoperative analgesia in patients with lung cancer undergoing video-assisted thoracoscopic lobectomy. Press needle stimulation is a feasible adjunct therapy for patients undergoing video-assisted thoracoscopic surgery.Using press needle stimulation reduces postoperative pulmonary complications.Press needle stimulation allows for improved pain control.Press needle stimulation may be an effective intervention for improving patient outcomes. Press needle stimulation is a feasible adjunct therapy for patients undergoing video-assisted thoracoscopic surgery. Using press needle stimulation reduces postoperative pulmonary complications. Press needle stimulation allows for improved pain control. Press needle stimulation may be an effective intervention for improving patient outcomes.
DOI: 10.6084/m9.figshare.30132047.v1
title: Effect of press needle stimulation on postoperative pulmonary complications in video-assisted thoracoscopic surgery patients: a randomized controlled trial

description: Patients undergoing high-risk surgical procedures frequently experience postoperative pulmonary complications (PPCs) that impact outcomes. Acupuncture has demonstrated potential benefits during surgery. Press needle stimulation is increasingly recognized as an alternative to conventional techniques. We aimed to evaluate the effect of press needle stimulation on PPCs in patients with lung cancer undergoing video-assisted thoracoscopic surgery. Eighty-seven patients undergoing video-assisted thoracoscopic surgery were randomized into press needle (<i>n</i> = 48) or sham needle (<i>n</i> = 39) groups. The press needle group underwent bilateral stimulation of acupoints LU9 (Taiyuan), RN17 (Danzhong), LU6 (Kongzui), and BL13 (Feishu) before anesthesia and during surgery. The sham group received a placebo stimulation. The primary endpoint was the incidence of PPCs within seven days post-surgery. The secondary endpoints included cytokine levels, intraoperative respiratory mechanics, postoperative pain score, analgesic consumption, and related complications. Press needle acupoint stimulation was associated with a significantly lower incidence of PPCs than the sham needle group. Perioperative data, tachycardia, cough, postoperative nausea, vomiting, and most inflammatory markers exhibited no significant differences, except for lower hypoxia-inducible factor-1<i>α</i> levels in the press needle group. Hemodynamic and blood gas analyses indicated no significant cardiovascular or respiratory differences between groups. The press needle group exhibited reduced patient-controlled analgesia (PCA) pump utilization and lower total PCA usage, indicating improved pain management. This study indicates that press needle stimulation lowers PPC incidence and improves postoperative analgesia in patients with lung cancer undergoing video-assisted thoracoscopic lobectomy. Press needle stimulation is a feasible adjunct therapy for patients undergoing video-assisted thoracoscopic surgery.Using press needle stimulation reduces postoperative pulmonary complications.Press needle stimulation allows for improved pain control.Press needle stimulation may be an effective intervention for improving patient outcomes. Press needle stimulation is a feasible adjunct therapy for patients undergoing video-assisted thoracoscopic surgery. Using press needle stimulation reduces postoperative pulmonary complications. Press needle stimulation allows for improved pain control. Press needle stimulation may be an effective intervention for improving patient outcomes.